Abeona Therapeutics (ABEO) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Abeona Therapeutics Revenue Highlights


00

Main Segment (Y)

License and Other Revenues

Main Geography (Y)

License and Other Revenues

Abeona Therapeutics Revenue by Period


Abeona Therapeutics Revenue by Year

DateRevenueChange
2024-12-31--100.00%
2023-12-31$3.50M147.52%
2022-12-31$1.41M-52.87%
2021-12-31$3.00M-70.00%
2020-12-31$10.00M100.00%
2019-12-31--100.00%
2018-12-31$3.00M258.18%
2017-12-31$837.00K-5.85%
2016-12-31$889.00K-14.52%
2015-12-31$1.04M12.43%
2014-12-31$925.00K-54.70%
2013-12-31$2.04M-53.63%
2012-12-31$4.40M138.31%
2011-12-31$1.85M284.20%
2010-12-31$481.00K36.65%
2009-12-31$352.00K20.96%
2008-12-31$291.00K410.53%
2007-12-31$57.00K100.00%
2006-12-31-100.00%
2005-12-31--100.00%
2004-12-31$549.00K-57.61%
2003-12-31$1.29M12.90%
2002-12-31$1.15M372.02%
2001-12-31$243.00K127.10%
2000-12-31$107.00K613.33%
1999-12-31$15.00K-85.00%
1998-12-31$100.00K-77.01%
1997-12-31$435.00K160.48%
1996-12-31$167.00K-94.33%
1995-12-31$2.94M-

Abeona Therapeutics generated - in revenue during NA 2024, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Abeona Therapeutics Revenue by Quarter

DateRevenueChange
2025-09-30--100.00%
2025-06-30$400.00K100.00%
2025-03-31--100.00%
2024-12-31$4.78M100.00%
2024-09-30-100.00%
2024-06-30-100.00%
2024-03-31--100.00%
2023-12-31$2.82M100.00%
2023-09-30--100.00%
2023-06-30$3.50M100.00%
2023-03-31--100.00%
2022-12-31$68.00K100.00%
2022-09-30--100.00%
2022-06-30$1.00M189.02%
2022-03-31$346.00K-88.47%
2021-12-31$3.00M100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31--100.00%
2020-12-31$3.00M-57.14%
2020-09-30$7.00M100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31--100.00%
2018-12-31$-2.13M-224.52%
2018-09-30$1.71M519.20%
2018-06-30$276.00K-89.38%
2018-03-31$2.60M1108.37%
2017-12-31$215.00K-1.83%
2017-09-30$219.00K0.92%
2017-06-30$217.00K16.67%
2017-03-31$186.00K-27.34%
2016-12-31$256.00K39.13%
2016-09-30$184.00K-14.02%
2016-06-30$214.00K-8.94%
2016-03-31$235.00K9.30%
2015-12-31$215.00K-24.56%
2015-09-30$285.00K1.06%
2015-06-30$282.00K9.30%
2015-03-31$258.00K10.26%
2014-12-31$234.00K-0.85%
2014-09-30$236.00K-4.45%
2014-06-30$247.00K18.75%
2014-03-31$208.00K28.40%
2013-12-31$162.00K-14.29%
2013-09-30$189.00K-59.53%
2013-06-30$467.00K-61.85%
2013-03-31$1.22M21.67%
2012-12-31$1.01M15.50%
2012-09-30$871.00K26.23%
2012-06-30$690.00K-62.80%
2012-03-31$1.85M266.60%
2011-12-31$506.00K-51.39%
2011-09-30$1.04M589.40%
2011-06-30$151.00K0.67%
2011-03-31$150.00K2.04%
2010-12-31$147.00K15.75%
2010-09-30$127.00K20.95%
2010-06-30$105.00K2.94%
2010-03-31$102.00K-1.92%
2009-12-31$104.00K-27.78%
2009-09-30$144.00K128.57%
2009-06-30$63.00K53.66%
2009-03-31$41.00K-44.59%
2008-12-31$74.00K57.45%
2008-09-30$47.00K-64.39%
2008-06-30$132.00K247.37%
2008-03-31$38.00K-25.49%
2007-12-31$51.00K-

Abeona Therapeutics generated - in revenue during Q3 2025, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Abeona Therapeutics Revenue Breakdown


Abeona Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 21Dec 20Dec 18
License and Other Revenues$3.00M$10.00M-
Foundation--$5.71M
License--$602.00K

Abeona Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 21: License and Other Revenues (100.00%).

Quarterly Revenue by Product

Product/ServiceDec 18Sep 18Jun 18
Royalty$113.00K$22.00K$17.00K
Grant$369.00K$1.69M$802.00K

Abeona Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 18: Grant (76.56%), and Royalty (23.44%).

Abeona Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 21Dec 20Dec 18
License and Other Revenues$3.00M$10.00M-
Foundation--$5.71M
License--$602.00K

Abeona Therapeutics's latest annual revenue breakdown by geography, as of Dec 21: License and Other Revenues (100.00%).

Quarterly Revenue by Country

CountryDec 18Sep 18Jun 18
Royalty$113.00K$22.00K$17.00K
Grant$369.00K$1.69M$802.00K

Abeona Therapeutics's latest quarterly revenue breakdown by geography, as of Dec 18: Grant (76.56%), and Royalty (23.44%).

Abeona Therapeutics Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
PBYIPuma Bio$230.47M$54.48M
ARCTArcturus Therapeutics$152.31M$17.15M
VYGRVoyager Therapeutics$80.00M$13.37M
FHTXFoghorn Therapeutics$22.60M$8.15M
TNYATenaya Therapeutics--
ABEOAbeona Therapeutics--
HUMAHumacyte-$753.00K
ASMBAssembly Biosciences--
SGMTSagimet Biosciences--
ELDNEledon Pharmaceuticals--

ABEO Revenue FAQ


What is Abeona Therapeutics’s yearly revenue?

Abeona Therapeutics's yearly revenue for 2024 was $0, representing a decrease of -100.00% compared to 2023. The company's yearly revenue for 2023 was $3.5M, representing an increase of 147.52% compared to 2022. ABEO's yearly revenue for 2022 was $1.41M, representing a decrease of -52.87% compared to 2021.

What is Abeona Therapeutics’s quarterly revenue?

Abeona Therapeutics's quarterly revenue for Q3 2025 was $0, a -100.00% decrease from the previous quarter (Q2 2025), and a 0% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $400K, a 100.00% increase from the previous quarter (Q1 2025), and a 0% increase year-over-year (Q2 2024). ABEO's quarterly revenue for Q1 2025 was $0, a -100.00% decrease from the previous quarter (Q4 2024), and a 0% increase year-over-year (Q1 2024).

What is Abeona Therapeutics’s revenue growth rate?

Abeona Therapeutics's revenue growth rate for the last 3 years (2022-2024) was -100.00%, and for the last 5 years (2020-2024) was -100.00%.

What are Abeona Therapeutics’s revenue streams?

Abeona Therapeutics's revenue streams in c 21 are License and Other Revenues

What is Abeona Therapeutics’s main source of revenue?

For the fiscal year ending Dec 21, the largest source of revenue of Abeona Therapeutics was License and Other Revenues. This segment made a revenue of $3M, representing 100.00% of the company's total revenue.